DV
Dividend Vision

QNTM — Quantum BioPharma Ltd.

Quantum BioPharma Ltd. (QNTM)

Its deepest 1-year drawdown was 91.0%.

Quantum BioPharma Ltd. is a biopharmaceutical company developing drug candidates for neurodegenerative, inflammatory, metabolic, and alcohol misuse disorders, with its lead asset Lucid-MS in Phase 2 trials for multiple sclerosis treatment; the company also maintains a portfolio of strategic investments in residential property-secured loans. The company does not currently distribute dividends or other payments to shareholders. This security appeals primarily to investors seeking exposure to early-stage biotech development rather than those focused on dividend income.

QNTM key facts

Asset type
Stock
Asset class
Equity
Inception date
06/08/2018
Last close
$3.80
Market cap
$19,323,914
Average volume
273000.0
Beta
0.44
Payout ratio
0.0
Forward P/E
0.0
EPS
$-7.58